Carbohydrate antigen 19–9 is significantly elevated in autosomal dominant polycystic kidney disease. Issue 3 (20th February 2018)

• Record Type: Journal Article
• Authors: Fukasawa, Hirotaka; Kaneko, Mai; Niwa, Hiroki; Yasuda, Hideo; Kumagai, Hiromichi; Furuya, Ryuichi
• Is Part Of: Nephrology. Volume 23:Issue 3(2018)
• Page Start: 210
• Page End: 216
• Publication Date: 2018-02-20
• Subjects: autosomal dominant polycystic kidney disease (ADPKD) -- carbohydrate antigen 19–9 (CA19–9) -- cyst volume -- gamma‐glutamyl transferase (GTP) -- liver cysts; Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.12988
• Languages: English
• ISSNs: 1320-5358

Abstract

Abstract: Aim: Liver cysts are the most common extrarenal manifestation in patients with autosomal dominant polycystic kidney disease (ADPKD). Carbohydrate antigen 19–9 (CA19–9) is generally used as a marker for biliopancreatic malignancies, although CA19–9 levels in patients with ADPKD are largely unknown. Methods: A prospective observational study of 53 ADPKD patients and 83 non‐ADPKD control subjects was performed. The serum levels of CA19–9 were studied to evaluate the association with clinical parameters and liver cysts. Results: The serum CA19–9 levels were significantly higher in the ADPKD group than in the control group (32.9 U/mL vs. 9.8 U/mL, respectively, P < 0.001). The serum CA19–9 levels in the ADPKD group were positively correlated with the mean blood pressure ( rho = 0.335, P < 0.05), gamma‐glutamyl transferase (GTP) levels ( rho = 0.541, P < 0.001), the largest cyst size ( rho = 0.536, P < 0.001) and the liver cyst volume ( rho = 0.682, P < 0.001). Multiple regression analyses showed that the gamma‐GTP levels ( P < 0.001) and the liver cyst volumes ( P < 0.001) were independent predictors for serum CA19–9 levels. Conclusions: Serum CA19–9 levels are significantly elevated and appear to be dependent on the gamma‐GTP levels and the volume of liver cysts in patients with ADPKD. Our findings indicate that the measurement of the baseline CA19–9 level in each patient with ADPKD may be useful for the interpretation of the value and the differential diagnosis of liver diseases, particularly the liver cyst infection. Summary at a Glance: This prospective observational study demonstrates that serum CA‐19.9 levels may be increased up to 3‐fold in CKD patients with ADPKD compared to those without ADPKD.